Apelin: an antithrombotic factor that inhibits platelet function


Apelin: an antithrombotic factor that inhibits platelet function.

Adam F, Khatib AM, Lopez JJ, Vatier C, Turpin S, Muscat A, Soulet F, Aries A, Jardin I, Bobe R, Stepanian A, de Prost D, Dray C, Rosado JA, Valet P, Feve B, Siegfried G.

Blood. 2016 Feb 18;127(7):908-20. doi: 10.1182/blood-2014-05-578781. Epub 2015 Dec 3.

« Un médicament anticoagulant inédit (PDF) »
Article du Parisien du vendredi 12 février 2016

« L’Apeline contre la thrombose (PDF) »
Actualités Inserm News


Apelin peptide and its receptor APJ are directly implicated in various physiological processes ranging from cardiovascular homeostasis to immune signaling. Here, we show that apelin is a key player in hemostasis with an ability to inhibit thrombin- and collagen-mediated platelet activation. Mice lacking apelin displayed a shorter bleeding time and a prothrombotic profile. Their platelets exhibited increased adhesion and a reduced occlusion time in venules, and displayed a higher aggregation rate after their activation by thrombin compared with wild-type platelets. Consequently, human and mouse platelets express apelin and its receptor APJ. Apelin directly interferes with thrombin-mediated signaling pathways and platelet activation, secretion, and aggregation, but not with ADP and thromboxane A2-mediated pathways. IV apelin administration induced excessive bleeding and prevented thrombosis in mice. Taken together, these findings suggest that apelin and/or APJ agonists could potentially be useful adducts in antiplatelet therapies and may provide a promising perspective for patients who continue to display adverse thrombotic events with current antiplatelet therapies.

© 2016 by The American Society of Hematology.

Contact :
Majid Khatib / majid.khatib@inserm.fr

LOGO-UNIVERSITE-BORDEAUX inserm57x16mmHD logo cnrs chu bergoni
Mentions Légales